Drug Trial Radar · NCT05846867
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
May 8, 2023
Primary completion
May 8, 2026
Study completion Aug 11, 2026
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC
Conditions
- Colorectal Cancer
Interventions
AK119Drug
AK119 IV every 2 weeks.intravenous infusion
AK112Drug
AK112 IV every 2 weeks.intravenous infusion
OxaliplatinDrug
Oxaliplatin: 85mg/m2, intravenous infusion
IrinotecanDrug
Irinotecan 180mg/m2, intravenous infusion
Calcium folinateDrug
Calcium folinate: 400mg/m2, intravenous infusion
FluorouracilDrug
Fluorouracil 400mg/m2, intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to 2 years
- Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
- recommended phaseII doseTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Affiliated to Harbin Medical University
Harbin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.